Merck Raises 2026 Revenue Outlook, Lowers Profit Guidance on Terns Charges
Merck raised its 2026 revenue outlook to $66.3 billion to $67.3 billion, compared with prior guidance of $65.8 billion to $67 billion. Adjusted earnings per share are now $2.66 to $2.76, including a $5.7 billion one-time charge tied to the Terns deal, after posting a $1.34 billion net loss for the quarter. Keytruda sales rose to $8.37 billion.